{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:28:32Z","timestamp":1792625312156,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MCNALL19K0"],"award-info":[{"award-number":["MCNALL19K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["VIA118"],"award-info":[{"award-number":["VIA118"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023551","name":"Cystic Fibrosis Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:24:46Z","timestamp":1696649086000},"page":"474-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years \u2013 The RECOVER study"],"prefix":"10.1016","volume":"23","author":[{"given":"Jochen G.","family":"Mainz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8813-710X","authenticated-orcid":false,"given":"Karen","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8794-5100","authenticated-orcid":false,"given":"Basil","family":"Elnazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"McKone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-7178","authenticated-orcid":false,"given":"Des","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Linnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Zagoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Duckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Barucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-1712","authenticated-orcid":false,"given":"Paul","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2023.10.001_bib0001","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.pcl.2016.04.008","article-title":"Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis","volume":"63","author":"Sathe","year":"2016","journal-title":"Pediatr Clin North Am"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198457","article-title":"Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis","volume":"13","author":"de Freitas","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2023.10.001_bib0003","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcf.2017.07.014","article-title":"Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine","volume":"16","author":"Dorsey","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174463","article-title":"Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings","volume":"12","author":"Tabori","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.001_bib0005","doi-asserted-by":"crossref","first-page":"17465","DOI":"10.1038\/s41598-017-17302-4","article-title":"Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients","volume":"7","author":"Tabori","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.001_bib0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"Patient"},{"key":"10.1016\/j.jcf.2023.10.001_bib0007","article-title":"Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","author":"Moshiree","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.001_bib0008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MPG.0000000000001544","article-title":"Fecal Calprotectin in Cystic Fibrosis and Its Relation to Disease Parameters: A Longitudinal Analysis for 12 Years","volume":"65","author":"Ellemunter","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.001_bib0009","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MPG.0000000000003357","article-title":"Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis","volume":"74","author":"Jaudszus","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.001_bib0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.10.001_bib0011","unstructured":"Administration USDoHaHSFaD. GUIDANCE DOCUMENT: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009 10\/17\/2019."},{"issue":"7","key":"10.1016\/j.jcf.2023.10.001_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcf.2023.10.001_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.001_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.jcf.2023.10.001_bib0015","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jcf.2023.10.001_bib0016","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.001_bib0017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.jcf.2023.10.001_bib0018","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.10.001_bib0019","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"17","key":"10.1016\/j.jcf.2023.10.001_bib0020","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.001_bib0021","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.jcf.2023.10.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.10.001_bib0023","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.10.001_bib0024","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacftor\/Ivacaftor in People with Cystic Fibrosis","author":"Nichols","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.10.001_bib0025","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.001_bib0026","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1513\/AnnalsATS.202006-614RL","article-title":"Appearance of Pancreatic Sufficiency and Discontinuation of Pancreatic Enzyme Replacement Therapy in Children with Cystic Fibrosis on Ivacaftor","volume":"18","author":"Hutchinson","year":"2021","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.jcf.2023.10.001_bib0027","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","author":"Nichols","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.001_bib0028","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.001_bib0029","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2023.10.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2 Through 5 Years with Cystic Fibrosis and at Least One F508del Allele","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.10.001_bib0031","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","author":"Schwarzenberg","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2023.10.001_bib0032","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.10.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225004","article-title":"Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents","volume":"14","author":"Boon","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jcf.2023.10.001_bib0034","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/2050640619841545","article-title":"A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders","volume":"7","author":"Hayee","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.001_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jpepsy\/25.6.403","article-title":"Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis","volume":"25","author":"Quittner","year":"2000","journal-title":"J Pediatr Psychol"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.001_bib0036","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ppul.26318","article-title":"Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis","volume":"58","author":"McCoy","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.001_bib0037","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12029-018-0088-1","article-title":"Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer","volume":"50","author":"Dabbous","year":"2019","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.jcf.2023.10.001_bib0038","first-page":"99","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","volume":"35","author":"Nichols","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"10212","key":"10.1016\/j.jcf.2023.10.001_bib0039","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.10.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Scientific reports"},{"issue":"12","key":"10.1016\/j.jcf.2023.10.001_bib0041","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.10.001_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.642180","article-title":"Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid","volume":"12","author":"Mainz","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.001_bib0043","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5\u00a0years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.001_bib0044","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcf.2013.05.006","article-title":"Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation","volume":"12","author":"Hebestreit","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.10.001_bib0045","unstructured":"Ooi C, Garg M, Young K, Needham B, Leach S, Jaffe A, et\u00a0al. Improvement in Intestinal Inflammation on Ivacaftor. 2016;51:272-."},{"issue":"11","key":"10.1016\/j.jcf.2023.10.001_bib0046","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/ibd.20214","article-title":"Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation","volume":"13","author":"Chung-Faye","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.001_bib0047","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/jgh.12842","article-title":"Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?","volume":"30","author":"Pang","year":"2015","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"7","key":"10.1016\/j.jcf.2023.10.001_bib0048","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1039\/D1MD00045D","article-title":"Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents","volume":"12","author":"Rathod","year":"2021","journal-title":"RSC Med Chem"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.001_bib0049","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djs481","article-title":"Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States","volume":"105","author":"Maisonneuve","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jcf.2023.10.001_bib0050","article-title":"Roadmap to Pyruvate Kinase M2 Modulation - A Computational Chronicle","author":"Kapoor","year":"2023","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jcf.2023.10.001_bib0051","article-title":"The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: An English population-based study","author":"Birch","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2023.10.001_bib0052","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093133","article-title":"What Role Does CFTR Play in Development, Differentiation, Regeneration and Cancer?","volume":"21","author":"Amaral","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:32:02Z","timestamp":1777649522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323009220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199323009220"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.10.23292435","asserted-by":"object"}]},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years \u2013 The RECOVER study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}